Huntington Bancshares Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Huntington Bancshares Incorporated on January 28, 2026. The report details a significant capital market transaction involving the issuance of new debt securities to raise capital.
Key Financial Metrics and Transaction Details
The Company issued and sold a total of $1.75 billion in aggregate principal amount of notes on January 28, 2026. The specific instruments issued are as follows:
- Senior Notes: $1,000,000,000 aggregate principal amount of 4.623% Fixed-to-Floating Rate Senior Notes due 2032.
- Subordinated Notes: $750,000,000 aggregate principal amount of 5.605% Fixed-to-Fixed Rate Subordinated Notes due 2041.
The underwriters for this transaction included Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Huntington Securities, Inc.
Material Changes
This filing represents a material increase in the Company's debt obligations. The issuance adds $1.75 billion to the Company's capital structure, consisting of both senior and subordinated debt tranches with varying maturity dates and interest rate structures.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, management commentary on future earnings, or a discussion of general business risks. The primary focus is the legal and structural details of the debt issuance. The transaction was executed pursuant to an underwriting agreement dated January 23, 2026, and the notes were sold under existing indentures supplemented by new agreements dated January 28, 2026.
Key Facts for Investor Verification
- Verify the total proceeds received from the $1.75 billion issuance after deducting underwriting discounts and commissions.
- Review the specific terms of the "Fixed-to-Floating" and "Fixed-to-Fixed" interest rate mechanisms to understand future interest expense volatility.
- Confirm the impact of the new debt on the Company's leverage ratios and liquidity position.
- Examine the prospectus supplement filed on January 27, 2026, for detailed use of proceeds and risk factors associated with the new notes.